GSK’s follow-up to its severe asthma therapy Nucala has shown its value in a pair of phase 3 trials, reducing exacerbations compared to placebo with dosing once every six
Johnson & Johnson has agreed a $850 million deal to acquire Proteologix that will give it a pair of early-stage bispecific antibodies with immunology applications, inc
New start-up Uniquity Bio arrived on the scene today with $300 million in funding from Blackstone Life Sciences and a clinical-stage inflammation and immunology drug licen
A high-tech device that can monitor medication use and compliance has been cleared by the FDA for use with AstraZeneca’s Airsupra and Breztri inhalers.
President Joe Biden has reiterated his pledge to take action against high drug prices and “beat big pharma,” singling out the cost of asthma inhalers in a speech delivered
RAPT Therapeutics has seen its shares fall sharply after the FDA placed a clinical hold on oral CCR4 antagonist zelnecirnon, currently in a phase 2b trial for atopic derma
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh